Clinical Trials Logo

Recurrent Miscarriage clinical trials

View clinical trials related to Recurrent Miscarriage.

Filter by:

NCT ID: NCT03710226 Completed - Clinical trials for Recurrent Miscarriage

Use of Platelet Indices for Prediction of Recurrent Miscarriage

Start date: January 1, 2019
Phase:
Study type: Observational

Platelet indices might be a marker for platelet activation, and thus could predict thrombosis. This might be the cause in some cases of recurrent miscarriage. This study aims to evaluate the use of platelet indices -as a simple test- to predict recurrent miscarriage.

NCT ID: NCT03209063 Not yet recruiting - Clinical trials for Recurrent Miscarriage

The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage

Start date: July 1, 2022
Phase:
Study type: Observational

Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss(RPL) usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full reproductive period) . In 2012, the American Society for Reproductive Medicine Practice Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies.approximately 40% of couples will have an etiology identified that could be associated with their loss.

NCT ID: NCT03165136 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Hydroxychloroquine for Prevention of Recurrent Miscarriage.

BBQ
Start date: December 4, 2017
Phase: Phase 3
Study type: Interventional

Recurrent miscarriage (RM) defined by >=3 consecutive losses affects 1% of fertile couples. Most women have recurrent early loss with a failure of development before 10 weeks' gestation. Standard investigations fail to reveal any apparent cause in >50% of couples. No study has demonstrated any benefit of any medication in women with Unexplained RM, in the presence or absence of an inherited thrombophilia. Moreover, the benefit of aspirin and/or heparin has not been proved in women with Antiphospholipid (APL) antibody without other clinical manifestations of Antiphospholipid Syndrome. Hydroxychloroquine (HQ) is a molecule whose properties (anti-thrombotic, vascular-protective, immunomodulatory, improved glucose tolerance, lipid-lowering, anti-infectious) could be useful against mechanisms of Unexplained RM. There is no data concerning the benefit of HQ in RM in the presence or absence of antiphospholipid antibodies or any inherited thrombophilia. Administration in (Systemic Lupus erythematosus (SLE) women and for Malaria prevention provides extensive safety data during pregnancy. Oral administration makes possible treatment since the preconception period. For all of that and its low cost, hydroxychloroquine should be evaluated in RM whatever the woman thrombophilic status.

NCT ID: NCT03132779 Not yet recruiting - Clinical trials for Recurrent Miscarriage

Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

Evaluating the effect of intralipid on the natural killer cells

NCT ID: NCT03023137 Completed - Clinical trials for Recurrent Miscarriage

Walking and Dietary Modification for Recurrent Early Miscarriages

W&D
Start date: May 2011
Phase: N/A
Study type: Interventional

This study is part of a big one aiming to evaluate how lifestyle interventions during pregnancy affect obstetric results, neonatal metabolism and the intelligence of the offspring (study not yet completed). Data regarding obstetric and neonatal results were entered in NCT01409382, but we decided to split results in two for the sake of clarity. A cohort of women with early pregnancy losses without antiphospholipid antibodies was selected for two reasons. One is that these women follow strictly the recommendadtions. The second is that no medication has been shown to increase the rate of take-home babies in women with early miscarriages who test negative for antiphospholipid antibodies. We decided to focus on the fibrinolytic system because trophoblast migration and placental vasculogenesis and angiogenesis depend on plasmin-dependent extracellular matrix remodeling. Plasminogen activator inhibitor (PAI)-1 inhibits the generation of plasmin. Since both glucose and insulin increase PAI-1 synthesis, hyperglycemia itself, or by stimulating insulin production, reduces plasmin generation, which may impair placentation. Abnormalities in glucose metabolism may be also deleterious to embryos by causing epigenetic changes. Chromosomal abnormalities are considered an important cause of early pregnancy losses. Several lines of evidence lend support to the hypothesis that carbohydrate metabolism abnormalities contribute to the pathogenesis of recurrent early pregnancy losses. One is that of the pregnancies of the women with polycystic ovary syndrome, around 30 and 50% end with first-trimester miscarriages. Hyperinsulinemia is a prevalent feature of the syndrome, and interventions proven effective in reducing insulin levels, such as metformin, have been shown to reduce the rate of early miscarriages. The other is that patients with body mass index of ≥25 kg/m2 have significantly higher odds of early miscarriage, regardless of the method of conception. The investigator's hypothesis was that a balanced diet combined to regular exercise, by improving glucose homeostasis, would increase the take-home baby rate in women with consecutive early miscarriages. Moderate exercises are usually well tolerated not only by the mother, but also by the fetus, as indicated by tests of fetal well-being, including umbilical artery systolic to diastolic ratio.

NCT ID: NCT02946177 Enrolling by invitation - Infertility Clinical Trials

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

DE-FluVac
Start date: January 19, 2017
Phase: Phase 4
Study type: Interventional

In this study the investigators propose a randomized controlled trial to evaluate the effect of influenza vaccination on clinical pregnancy rates among women undergoing in vitro fertilization as donor egg recipients.

NCT ID: NCT02694367 Completed - Clinical trials for Recurrent Miscarriage

Expression of EPK in Recurrent Miscarriage

EPK-RM
Start date: January 2015
Phase: N/A
Study type: Observational

The present study is based on hypotheses that some as yet unknown genetic factors may result in recurrent miscarriage (RM). Consequently, the main aim of this study was to gain new information about the underlying genetic causes of RM in the Egyptian population and to investigate the expression of ERK and p-ERK protein in human placenta and their corresponding tissue, to assess the significance of MAPK signal pathway in progression of recurrent miscarriage and PI3K-Akt Pathway.

NCT ID: NCT02681627 Completed - Clinical trials for Recurrent Miscarriage

Sim (Scratch in Miscarriage) Study

SiM
Start date: November 30, 2015
Phase: N/A
Study type: Interventional

There is increasing amount of evidence which suggests that miscarriage is related to a primary endometrial problem. Recent cochrane meta-analysis (March 2015) has proven that endometrial scratch improves live birth in women who underwent IVF. The aim of the study is to find out if scratch of the endometrium prevents recurrent miscarriage.

NCT ID: NCT02504281 Completed - Clinical trials for Recurrent Miscarriage

Study on the Association Between SXCI and RM and the Possible Genetic Mechanism

Start date: January 2015
Phase:
Study type: Observational

To determine whether there is higher incidence of skewed X chromosome inactivation(SXCI) in the recurrent miscarriage(RM) population compared with normal population, and verify the existing hypothesis of the possible genetic mechanisms underlying the association between SXCI and RM.

NCT ID: NCT02326051 Completed - Clinical trials for Antiphospholipid Syndrome

Timing of Initiation of LMWH Administration in Pregnant Women With APS

Start date: December 2014
Phase: Phase 4
Study type: Interventional

Evaluation of the effect of altering the timing of initiation of low molecular weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS)